Welcome! - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Welcome!


Pharmaceutical Technology Europe
Volume 24, Issue 6


Dr Jo Watts
It is with real pleasure that I join the Pharmaceutical Technology Europe (PTE) team. I am honoured to be the Editor of this magazine, especially at such an exciting time. This year celebrates the 35th anniversary of the Pharmaceutical Technology brand, an event that will be celebrated with special feature articles that evaluate the last three and a half decades of developments in the pharmaceutical industry (be sure to check out http://PharmTech.com/ in July for the celebratory retrospectives).

Given the current economic climate, none of us can foresee what the future holds for the industry, but our editorial team will endeavour to continue bringing you relevant, topical and unbiased information. As Editor, I will undertake providing you with engaging, enjoyable content that you will find both interesting and beneficial.

I look forward to meeting some of you at industry events in the coming months and hearing your views on what we can do to make your job easier. We welcome your feedback and participation in our online PharmTechGroup communities on LinkedIn and Twitter.

This month also sees the next ACHEMA event. In current economic times such shows can seem a financial burden, but the chance to meet people face-to-face is becoming less frequent, and to have such large numbers from the industry all under one roof is a compelling enough reason to attend. This year, the majority of the PTE team will be attending the show in Frankfurt. Visit us in hall 3.1, stand J25. You are more than welcome to visit us to let us know what's happening in your corner of the market, or to tell us about something exciting you've seen.

I would like to thank you, European Pharmaceutical Technologists, for your continued support of PTE over the years. With your constant input we will go on making PTE the successful magazine that it is.

Many thanks and best wishes,
Jo Watts, Editor

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Source: Pharmaceutical Technology Europe,
Click here